Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Leigh Ann Medaris"'
Autor:
Megan M. Petteys, Leigh Ann Medaris, Julie E. Williamson, Rohit S. Soman, Travis A. Denmeade, William E. Anderson, Michael K. Leonard, Christopher M. Polk
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 2 (2022)
Antibiotic overuse is high in patients hospitalized with coronavirus disease 2019 (COVID-19) despite a low documented prevalence of bacterial infections in many studies. In this study evaluating 65 COVID-19 patients in the intensive care unit, empiri
Externí odkaz:
https://doaj.org/article/c73be081db7d489dbb9d3506264702aa
Autor:
Jacqueline Meredith, Leigh Ann Medaris, Lewis McCurdy, Kristin Fischer, Michael Leonard, Jennifer S. Priem, Lisa Davidson, Jennifer Onsrud, Marc A. Kowalkowski
Publikováno v:
Open Forum Infectious Diseases. 8
Background Telemedicine (TM) programs can be implemented to deliver specialty care through virtual platforms and overcome geographic/resource constraints. Few data exist to describe outcomes associated with TM-based infectious diseases (ID) managemen
Autor:
Megan Petteys, Leigh Ann Medaris, Julie E Williamson, Travis Denmeade, Rohit Soman, William E Anderson, Michael Leonard, Christopher Polk
Publikováno v:
Open Forum Infectious Diseases
Background Studies have shown the proportion of critically ill patients with COVID-19 receiving empiric antibiotics (ABX) greatly exceeds those with culture-proven bacterial co-infections. However, the benefits of continuing ABX in culture-negative (
Autor:
Alan C. Heffner, William E. Anderson, Rupal K. Jaffa, Leigh Ann Medaris, Kelly E Pillinger, John Hammer
Publikováno v:
The American journal of emergency medicine. 48
To determine if aztreonam as initial empiric treatment of adult septic shock is associated with increased mortality compared to the use of anti-pseudomonal beta-lactam agents.This was a multicenter, retrospective cohort study of 582 adult emergency d
Publikováno v:
Open Forum Infectious Diseases
Background Recent studies have suggested that combination therapy may be preferred to monotherapy for select patients with methicillin-resistant Staphylococcus aureus bacteremia (MRSA-B); however, direct comparison between various combination regimen
Autor:
William E. Anderson, Alan C. Heffner, Rupal K Jaffa, Leigh Ann Medaris, John Hammer, Kelly E Pillinger
Publikováno v:
Open Forum Infectious Diseases
Background Aztreonam is often given to patients with a documented β-lactam allergy in lieu of a first-line anti-pseudomonal β-lactam (APBL). However, aztreonam offers no gram positive coverage and data suggest that gram negative organisms have lowe
Autor:
Jacqueline Meredith, Lisa Davidson, Leigh Ann Medaris, Vivek Shastry, Kristin Fischer, Cesar Aviles, Allyson Cochran, Danya Roshdy, Rupal K Jaffa
Publikováno v:
Open Forum Infectious Diseases
Background Handshake stewardship has displayed promise in engaging providers in the pediatric population but literature in adults are lacking. Face-to-face interactions are proposed to improve antibiotic stewardship (ASP) efforts in challenging servi
Autor:
Danya Roshdy, Leigh Ann Medaris, Elizabeth Green, Tyler Ginn, Rupal K Jaffa, William E. Anderson
Publikováno v:
Open Forum Infectious Diseases
Background Echinocandins (ECH) are recommended first-line for initial therapy (IT) of candidemia (CD) over fluconazole (FLU) due to their broad spectrum of activity. This recommendation was made prior to widespread implementation of rapid diagnostic
Autor:
Erin Gentry, Chloe Sweeney, Cliff Collins, Leigh Ann Medaris, Lisa Davidson, Ryan Burns, Marc A. Kowalkowski, Melanie D. Spencer, Elizabeth Handy
Publikováno v:
Open Forum Infectious Diseases
Background At least 30% of antibiotics prescribed in the ambulatory setting are unnecessary, including high rates of overuse for acute respiratory infections (ARI). We designed and evaluated whether a multifaceted outpatient stewardship program lever
Publikováno v:
Open Forum Infectious Diseases
Background Emergency department (ED) providers frequently use fluoroquinolones (FQs) as first-line therapy for common infections in discharged patients. In 2016 the FDA issued a warning against FQ use for three common conditions: cystitis, bronchitis